Analysts review Arcutis Biotherapeutics Inc’s rating

Roman Campbell

Arcutis Biotherapeutics Inc’s recent filing unveils that its insider Burnett Patrick unloaded Company’s shares for reported $0.33 million on Dec 15 ’25. In the deal valued at $28.94 per share,11,500 shares were sold. As a result of this transaction, Burnett Patrick now holds 98,307 shares worth roughly $2.76 million.

Then, Patrick Burnett bought 11,500 shares, generating $332,851 in total proceeds.

Before that, Matsuda Masaru sold 1,657 shares. Arcutis Biotherapeutics Inc shares valued at $50,091 were divested by the insider at a price of $30.23 per share. As a result of the transaction, Matsuda Masaru now holds 150,641 shares, worth roughly $4.23 million.

Goldman initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Neutral in a research note published on July 25, 2025; the price target was $18. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late December with a ‘”a Buy”‘ rating. Jefferies began covering ARQT with “Buy” recommendation on August 28, 2024. Mizuho revised its rating on January 03, 2024. It rated ARQT as “a Buy” which previously was an “a Neutral”.

Price Performance Review of ARQT

On Tuesday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock fall -1.68% to $28.08. Over the last five days, the stock has lost -6.09%. Arcutis Biotherapeutics Inc shares have risen nearly 88.08% since the year began. Nevertheless, the stocks have risen 101.58% over the past one year. While a 52-week high of $31.77 was reached on 12/08/25, a 52-week low of $11.13 was recorded on 02/11/25.

Levels Of Support And Resistance For ARQT Stock

The 24-hour chart illustrates a support level at 27.64, which if violated will result in even more drops to 27.21. On the upside, there is a resistance level at 28.58. A further resistance level may holdings at 29.09.

How much short interest is there in Arcutis Biotherapeutics Inc?

A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2025-12-15, dropping by -0.48 million shares to a total of 13.24 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 13.72 million shares. There was a decline of -3.64%, which implies that there is a negative sentiment for the stock.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.